Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 11 of the 23 sources its claims cite were checked for support.
Abstract
Background: UK studies examining vitiligo burden and vitiligo-related healthcare resource utilization (HCRU) are lacking. Objective: To describe the incidence and prevalence of vitiligo, the demographic and clinical characteristics of patients with vitiligo, vitiligo burden, HCRU, incidence of mental health comorbidities and management strategies, including treatment patterns. Methods: This retrospective study used UK Clinical Practice Research Datalink and Hospital Episode Statistics databases to analyse patients with vitiligo from 1 January 2010 to 31 December 2021. Results: Among 17 239 incident patients, mean incidence of vitiligo was 0.16 (2010-2021) per 1000 person-years [PY; range 0.10 (2020-COVID-19) to 0.19 (2010/2013/2018)]; among 66 217 prevalent patients, prevalence increased from 0.21% (2010) to 0.38% (2021). The most common comorbidities recorded after vitiligo diagnosis were diabetes (19.4%), eczema (8.9%), thyroid disease (7.5%) and rheumatoid arthritis (6.9%). Mental health diagnoses recorded at any time included depression and/or anxiety (24.6%), depression (18.5%), anxiety (16.0%) and sleep disturbance (12.7%), and recorded after vitiligo diagnosis in 6.4%, 4.4%, 5.5% and 3.9%, respectively. Mental health comorbidities were more common in White (e.g. depression and/or anxiety 29.0%) than in Black (18.8%) and Asian (16.1%) patients. In adolescents, depression and/or anxiety was most commonly diagnosed after a vitiligo diagnosis than before (7.4% vs. 1.8%). Healthcare resources were used most frequently in the first year after vitiligo diagnosis (incident cohort), typically dermatology-related outpatient appointments (101.9/100 PY) and general practitioner consultations (97.9/100 PY). In the year after diagnosis, 60.8% of incident patients did not receive vitiligo-related treatment (i.e. topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids or phototherapy), increasing to 82.0% the next year; median time from diagnosis to first treatment was 34.0 months (95% confidence interval 31.6-36.4). Antidepressants and/or anxiolytics were recorded for 16.7% of incident patients in the year after diagnosis. In 2019, 85.0% of prevalent patients did not receive vitiligo-related treatments. Conclusion: Most patients were not on vitiligo-related treatments within a year of diagnosis, with the time to first treatment exceeding 2 years, suggesting that vitiligo may be dismissed as unimportant. New effective treatments, early initiation and psychological intervention and support are needed to reduce the vitiligo burden on patients. © 2024 The Author(s).
Overview
CoChat Summary
TL;DR
In a UK retrospective study using CPRD and HES data, mean vitiligo incidence was 0.16 per 1000 person-years from 2010–2021 and prevalence rose from 0.21% in 2010 to 0.38% in 2021. Most patients received no vitiligo-related treatment within a year of diagnosis, and median time to first treatment was 34.0 months.
Key findings
- Among 17,239 incident patients, mean incidence was 0.16 per 1000 person-years [range 0.10 (2020) to 0.19 (2010/2013/2018)]; among 66,217 prevalent patients, prevalence increased from 0.21% (2010) to 0.38% (2021).
- Comorbidities recorded after vitiligo diagnosis included diabetes (19.4%), eczema (8.9%), thyroid disease (7.5%) and rheumatoid arthritis (6.9%). Mental health diagnoses at any time included depression and/or anxiety (24.6%), depression (18.5%), anxiety (16.0%) and sleep disturbance (12.7%); recorded after vitiligo diagnosis in 6.4%, 4.4%, 5.5% and 3.9%, respectively. Depression and/or anxiety was more common in White patients (29.0%) than Black (18.8%) or Asian (16.1%) patients; in adolescents it was more commonly diagnosed after than before vitiligo (7.4% vs. 1.8%).
- Healthcare resource use was highest in the first year after diagnosis: dermatology-related outpatient appointments 101.9/100PY and GP consultations 97.9/100PY. In the first year after diagnosis, 60.8% of incident patients had no vitiligo-related treatment, increasing to ≥82.0% from the second year onward; median time from diagnosis to first treatment was 34.0 months (95% CI 31.6–36.4). In 2019, 85.0% of prevalent patients had no vitiligo-related treatment.
- Antidepressants and/or anxiolytics were recorded for 16.7% of incident patients in the year after diagnosis.
Methods
- Retrospective longitudinal study using UK Clinical Practice Research Datalink (CPRD Aurum) linked to Hospital Episode Statistics (HES), 1 January 2010 to 31 December 2021. The incident cohort included 17,239 patients aged ≥12 years with a first vitiligo diagnosis in 2010–2019; the prevalent cohort included 66,217 patients aged ≥12 years with a pre-existing diagnosis on 1 January of any year 2010–2021.
- Annual incidence was calculated per 1000 person-years and point prevalence on 1 January each year. Demographics and comorbidities were described for incident cases in the 5 years before and after diagnosis; HCRU was reported per 100 person-years; treatment patterns were identified from prescription/treatment records, including time to first, second and third vitiligo-related treatments.
- Treatment-pattern Sankey analysis included incident patients in the HES outpatient database diagnosed no later than 31 December 2018; a treatment gap was defined as 18 months without any treatment record. All analyses were descriptive.
Limitations
- The paper states that data did not contain prescription fulfilment, over-the-counter treatments, or private dermatologist appointments/prescriptions; hospital dermatologist treatment records were available only if continued by a GP; phototherapy capture in CPRD Aurum and HES outpatient databases may have been limited, potentially underestimating phototherapy utilization. The study lacked a control group, did not include patients aged <12 years, lacked vitiligo-specific extent measures and patient-reported outcomes/QoL such as VitiQoL, and diagnoses may have been made by GPs rather than dermatologists.
- Evident from the text: missing data were substantial for BMI (11,375 missing) and smoking status (9,651 missing), which the authors note hinders definitive conclusions on smoking. The descriptive observational design cannot establish causality.
- The authors also note possible under-representation of mental health diagnoses in Black and minority ethnic populations due to inequalities, barriers to accessing mental health services, and cultural stigma.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
5 Valid · 1 Not valid · 7 Not checked · 57 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As not all patients with vitiligo seek medical attention or treatment, the actual prevalence in the UK population may be higher than observed in this dataset.4”
§ Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK > Discussion
What the sources say
- Partly supportedcites [4] Mohr, 2021, Epidemiology of vitiligo – a dual population-based approach, Clin Epidemiol sourceExperimental — accuracy not yet measured
The Introduction says that patients with vitiligo may not seek medical attention and that this could cause claims data to underestimate true prevalence. The study examines German data, however, so it does not establish that the UK dataset underestimates prevalence for the same reason. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Comorbidities in patients with vitiligo in our study were most often higher than those reported in individuals without vitiligo from other studies (Figure 4).4,8,10,[17][18][19][20]”
§ Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK > Discussion
What the sources say
- Supportedcites [4] Mohr, 2021, Epidemiology of vitiligo – a dual population-based approach, Clin Epidemiol source
The Results, under 'Dermatologic Comorbidity of Vitiligo' (Tables 3 and 5; page not provided), compare people with and without vitiligo. Most listed comorbidities are more prevalent in the vitiligo groups, supporting this paper's use as a comparison study. The citing authors' finding about their own study is not assessed here. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] Sheth, 2013, Comorbidities associated with vitiligo: a ten-year retrospective study, Dermatology source
- Partly supportedcites [10] Thompson, 2022, The mental health associations of vitiligo: UK population-based cohort study, BJPsych Open sourceExperimental — accuracy not yet measured
The Discussion reports higher risks of new-onset depression and anxiety in people with vitiligo than in controls. But the Results table shows that most pre-existing mental health conditions had similar prevalence in the two groups, and the Discussion reports no association with several other conditions. The source therefore supports examples of higher psychological comorbidity, not the broader claim that comorbidities were most often higher. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mental health comorbidities were more common in White patients than their counterparts”
§ Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK > Comorbidities
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the HES-linked incident patients, in the first year, patients were recorded as having been prescribed TCS (29.1%),TCIs (11.8%) and oral corticosteroids (4.2%).”
§ Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK > Management strategy patterns
plainn = 741- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the HES-linked incident patients, in the first year, patients were recorded as having been prescribed TCS (29.1%),TCIs (11.8%) and oral corticosteroids (4.2%).”
§ Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK > Management strategy patterns
plainn = 741- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
28 more claims
Create a free account to see all 70 claims and every source verdict.
- Probably not a substantial claim. 30
- It may state two separate claims as one. 10
Citations
Cites
Bergqvist, C., & Ezzedine, K. (2020) · Dermatology · doi:10.1159/000506103 · Cited by 799
Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients
van den Boorn, J. G., Konijnenberg, D., Dellemijn, T. A. M., Wietze van der Veen, J. P., Bos, J. D., Melief, C. J. M., Vyth-Dreese, F. A., & Luiten, R. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.32 · Cited by 543
The Prevalence of Vitiligo: A Meta-Analysis
Zhang, Y., Cai, Y., Shi, M., Jiang, S., Cui, S., Wu, Y., Gao, X.-H., & Chen, H.-D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163806 · Cited by 292
Psychosocial effects of vitiligo: a systematic literature review
Ezzedine, K., Eleftheriadou, V., Jones, H., Bibeau, K., Kuo, F. I., Sturm, D., & Pandya, A. G. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00631-6 · Cited by 276
Self-citationDevelopment and validation of a vitiligo-specific quality-of-life instrument (VitiQoL)
Lilly, E., Lu, P. D., Borovicka, J. H., Victorson, D., Kwasny, M. J., West, D. P., & Kundu, R. V. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.01.038 · Cited by 187
Vitiligo prevalence and quality of life among adults in Europe, Japan, and the USA
Bibeau, K., Pandya, A. G., Ezzedine, K., Jones, H., Gao, J., Lindley, A., & Harris, J. E. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18257 · Cited by 137
Comorbidities associated with vitiligo: a ten-year retrospective study
Sheth, V. M., Guo, Y., & Qureshi, A. A. (2013) · Dermatology · doi:10.1159/000354607 · Cited by 128
British Association of Dermatologists guidelines for the management of people with vitiligo 2021
Eleftheriadou, V., Atkar, R., Batchelor, J., McDonald, B., Novakovic, L., Patel, J. V., Ravenscroft, J., Rush, E., Shah, D., Shah, R., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.20596 · Cited by 122
Self-citationThompson, A. R., Clarke, S. A., Newell, R. J., Gawkrodger, D. J., & The Appearance Research Collaboration (ARC) (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09828.x · Cited by 121
Self-citationOsinubi, O., Grainge, M. J., Hong, L., Ahmed, A., Batchelor, J. M., Grindlay, D., Thompson, A. R., & Ratib, S. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16049 · Cited by 119
Self-citationComorbidity profiles in association with vitiligo: a nationwide population‐based study in Taiwan
Chen, Y. T., Chen, Y. J., Hwang, C. Y., Lin, M. W., Chen, T. J., Chen, C. C., Chu, S. Y., Lee, D. D., Chang, Y. T., & Liu, H. N. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12870 · Cited by 107
Vitiligo is more than skin deep: a survey of members of the Vitiligo Society: Vitiligo: a survey
Talsania, N., Lamb, B., & Bewley, A. (2010) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2009.03765.x · Cited by 89
Quality of life in people with vitiligo: a systematic review and meta-analysis
Morrison, B., Burden-Teh, E., Batchelor, J. M., Mead, E., Grindlay, D., & Ratib, S. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15933 · Cited by 70
Hadi, A., Wang, J. F., Uppal, P., Penn, L. A., & Elbuluk, N. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.036 · Cited by 53
Patients’ perspective on current treatments and demand for novel treatments in vitiligo
Narayan, V. S., Uitentuis, S. E., Luiten, R. M., Bekkenk, M. W., & Wolkerstorfer, A. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16927 · Cited by 49
Gopal, K., Rao, G., & Kumar, Y. (2014) · Indian Dermatology Online Journal · doi:10.4103/2229-5178.142493 · Cited by 48
Epidemiology of vitiligo – a dual population-based approach
Mohr, N., Petersen, J., Kirsten, N., & Augustin, M. (2021) · Clinical Epidemiology · doi:10.2147/clep.s304155 · Cited by 41
Ezzedine, K., Sénéschal, J., Silva, A. D., Préaubert, N., Lamblin, A., Delattre, C., Emery, C., Nevoret, C., Finzi, J., Bouée, S., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19447 · Cited by 41
Self-citationThomsen, S. F., & Sørensen, L. T. (2010) · PubMed · Cited by 38
Ezzedine, K., Soliman, A. M., Li, C., Camp, H. S., & Pandya, A. G. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01001-2 · Cited by 35
The mental health associations of vitiligo: UK population-based cohort study
Thompson, A. R., Eleftheriadou, V., & Nesnas, J. (2022) · BJPsych Open · doi:10.1192/bjo.2022.591 · Cited by 22
Self-citationOsinubi, O., Grainge, M. J., Hong, L., Ahmed, A. R. S. M., Batchelor, J. M., Grindlay, D., Thompson, A. R., & Ratib, S. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16511 · Cited by 13
Self-citation
Cited by
Focusing on the Dark Side of the Moon: Involvement of the Nonlesional Skin in Vitiligo
Tulić, M. K., Kovacs, D., Bastonini, E., Briganti, S., Passeron, T., & Picardo, M. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.10.598 · Cited by 8
Feng, X., Jiang, S., Zou, X., Deng, Y., & Xie, J. (2025) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.70245 · Cited by 7
Identifying the Genetic Associations Between Diabetes Mellitus and the Risk of Vitiligo
Zhao, L., Hu, M., & Li, L. (2024) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s480199 · Cited by 8
Parikh, M., Fang, G., Poon, F., Kyeremeh, M., Cruz, D., Ki, K., Huang, S., Lin, S., Hong, C., & Chan, H. O. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1661554 · Cited by 7
Geçer, M. Ö., & Kaya, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-11448-2 · Cited by 4
Metadata
- Authors
- Eleftheriadou, V., Delattre, C., Chetty-Mhlanga, S., Lee, C., Girardat-Rotar, L., Khan, I., Mathew, A., & Thompson, A. R.
- Affiliations
- The Royal Wolverhampton NHS Trust (GB)
- Incyte Biosciences International , Morges , Switzerland
- IQVIA Real World Solutions , Basel , Switzerland
- IQVIA (United Kingdom) (GB)
- University of Warwick (GB)
- Incyte Biosciences UK Ltd , Leatherhead , UK
- Cardiff and Vale University Health Board (GB)
- Corresponding author
- Eleftheriadou, Viktoria
- ORCID
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-03-27
- Volume
- 191
- Issue
- 2
- Pages
- 216-224
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W4393220563
- Cited by
- 21
- References
- 22
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 5
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- British Journal of Dermatology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- Incyte Corporation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- vitiligo, disease burden, healthcare resource utilization, incidence and prevalence, psychiatric comorbidity, anxiety and depression, sleep disorders, treatment patterns, topical corticosteroids, topical calcineurin inhibitors, phototherapy, systemic therapy, health care access disparities, adolescents, ethnic disparities, diabetes comorbidity, atopic dermatitis, thyroid dysfunction, rheumatoid arthritis
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, United Kingdom, Humans, Infant, Longitudinal Studies, Male, Middle Aged, Patient Acceptance of Health Care, Retrospective Studies, Vitiligo, Comorbidity, Incidence, Prevalence, Cost of Illness, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.